FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
58.945,98 -862,94 (-1,44%)
Apogee Therapeutics, Inc. (APGE)
Dopo ore:
| Chiusura precedente | 45,86 |
| Aperto | 46,17 |
| Denaro | 47,02 x 100 |
| Lettera | 47,42 x 100 |
| Min-Max giorno | 44,53 - 47,47 |
| Intervallo di 52 settimane | 14,19 - 72,29 |
| Volume | |
| Media Volume | 698.069 |
| Capitalizzazione | 2,755B |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 85,80 |
GlobeNewswireApogee Announces Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology (EADV) Congress
SAN FRANCISCO, CA and WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other inflammatory and immunology (I&I) indications, today announced two abstracts co-written with Apogee’s research partner, Paragon Therapeutics, Inc., highlighting the company’s lead product candidate, APG777, a f
- GlobeNewswire
Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day
SAN FRANCISCO and WALTHAM, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology (I&I) indications, today announced that members of its management will participate in a fireside chat at the 2023 Stifel Virtual I&I Day on Wednesday, September 20th, 2023 at 9:30 a.m. ET
- GlobeNewswire
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into 4Q 2026 Phase 1 clinical trial initiated and first participant dosed ahead of schedule for lead product candidate, APG777, a fully optimized and half-life extended anti-IL-13 antibody for the treatment of atopic dermatitis Leadership further strengthened with appointments of industry leaders to its board of directors and executive team SAN FRANCISCO and WALTHAM, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE)
